Abstract 1746P
Background
On-call work is an inherent component of Oncology care. Managerial models focus on length of stay in calculating efficiency within hospitals. Ensuring compliance with the European Working Time Directives (EWTD) for doctors is a legal requirement for Hospitals. Calculations of required physician staff to provide overnight care is not necessarily based on numbers of patients to be cared for, nor the complexity of care. The acute oncology service (AOS) after-hours has to date been provided by the day-time medical team in whole. To improve safety and quality of the AOS for patients being seen after hours, as well as to comply with the EWTD, a change to shift-work for the 1st-on-call oncology doctor is planned in 7/23. We sought to quantify the impact on the service.
Methods
The numbers of non-consultant hospital doctors (NCHDs), with allowances for full staff and also allowing for annual and educational leave entitlements were gathered for 1) pre-shift work implementation and 2) post-implementation of shift work. The number of NCHDs multiplied by the hours available to the ambulatory services (day unit and outpatient clinics) were calculated per week for both service structures to produce the "available NCHD hours".
Results
Assuming the normal working day is 8am to 5pm, this change would result in the reduction of available NCHDs to the ambulatory oncology service from 270 available NCHD hours per week to 171 available NCHD hours once vacation and study leave are factored into the equation, despite the addition of one NCHD to the medical oncology team. This represents a 36% reduction in available staff yet with a likely continued increase in patient activity.
Conclusions
While modifying the after-hours service to shift-work augments availability of medical staff for the acutely unwell patient with cancer and achieves compliance with EWTD, it reduces the numbers of doctors available for a significant part of the day, placing more strain on those doctors trying to manage a similar number of patients in a safe and patient-focused manner. Changes to the after-hours service inadvertently has knock-on effects on the “Oncology Ecosystem” and may impact on future service quality. Adjustments to NCHD numbers to cover the predicted significant staff fall short of those required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont RCSI Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23